227. オスラー病 [臨床試験数:49,薬物数:69(DrugBank:21),標的遺伝子数:23,標的パスウェイ数:132

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04646356
(ClinicalTrials.gov)
October 20, 202020/10/2020Tacrolimus Crossover Trial for Hereditary Hemorrhagic Telangiectasia (HHT)Tacrolimus Crossover Trial for Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;Epistaxis NosebleedDrug: Tacrolimus capsule (low-dose);Drug: PlaceboSt. Michael's Hospital, TorontoUnited States Department of DefenseRecruiting18 YearsN/AAll30Phase 2Canada
2EUCTR2019-003585-40-NL
(EUCTR)
17/12/201930/09/2019Tacrolimus for bleeding in hereditary hemorrhagic telangiectasia patientsAn uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia - Tacrolimus for bleeding in HHT patients Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant inherited disease characterized by mucocutaneous telangiectasis. Telangiectasis predominantly observed in the nasal mucosa and gut, and are abnormal, thin walled blood vessel that can easily rupture leading to hemorrhage.
MedDRA version: 20.0;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
St. Antonius HospitalNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
20 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noNetherlands